Tonix Pharmaceuticals Shares Down 77.2% After Co. Announced It Will Stop Phase 3 HONOR Study Of Tonmya For PTSD: Study Will Stop Due To Inadequate Separation From Placebo At Week 12 But Co. Said Decision To Discontinue Study Was Unrelated To Safety
Benzinga Newsdesk